Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review

References

• Strader CR, Pearce CJ, Oberlies NH. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod 2011;74:900-7
   PubMed Web of Science ®Google Scholar
• Chiba K, Matsuyuki H, Maeda Y, et al. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol 2006;3:11-19
   PubMed Web of Science ®Google Scholar
• Mehling M, Johnson TA, Antel J, et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011;76:S20-7
   PubMed Web of Science ®Google Scholar
• Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011;69:759-77
   PubMed Web of Science ®Google Scholar
• Pitman MR, Woodcock JM, Lopez AF, et al. Molecular targets of FTY720 (fingolimod). Curr Mol Med 2012;12:1207-19
   PubMed Web of Science ®Google Scholar
• Liang J, Nagahashi M, Kim EY, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 2013;23:107-20
   PubMed Web of Science ®Google Scholar
• Scott LJ. Fingolimod: a review of its use in the management of relapsing–remitting multiple sclerosis. CNS Drugs 2011;25:673-98
   PubMed Web of Science ®Google Scholar
• Kunkel GT, Maceyka M, Milstien S, et al. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 2013;12:688-702
   PubMed Web of Science ®Google Scholar
• Nagahashi M, Hait NC, Maceyka M, et al. Sphingosine-1-phosphate in chronic intestinal inflammation and cancer. Adv Biol Regul 2014;54:112-20
   PubMedGoogle Scholar
• Patmanathan SN, Yap LF, Murray PG, et al. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod. J Cell Mol Med 2015;19:2329-40
   PubMed Web of Science ®Google Scholar
• Rincón R, Cristóbal I, Zazo S, et al. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget 2015;6:4299-314
   PubMed Web of Science ®Google Scholar
• Calin GA, di Iasio MG, Caprini E, et al. Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 2000;19:1191-5
   PubMed Web of Science ®Google Scholar
• Ruediger R, Pham HT, Walter G. Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene 2000;20:10-15
   Web of Science ®Google Scholar
• Ruediger R, Pham HT, Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene 2001;20:1892-9
   PubMed Web of Science ®Google Scholar
• Tamaki M, Goi T, Hirono Y, et al. PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers. Oncol Rep 2004;11:655-9
   PubMed Web of Science ®Google Scholar
• Suzuki K, Takahashi K. Reduced expression of the regulatory A subunit of serine/threonine protein phosphatase 2A in human breast cancer MCF-7 cells. Int J Oncol 2003;23:1263-8
   PubMed Web of Science ®Google Scholar
• Esplin ED, Ramos P, Martinez B, et al. The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function. Genes Chromosomes Cancer 2006;45:182-90
   PubMed Web of Science ®Google Scholar
• Wang SS, Esplin ED, Li JL, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998;282:284-7
   PubMed Web of Science ®Google Scholar
• Junttila MR, Puustinen P, Niemelä M, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007;130:51-62
   PubMed Web of Science ®Google Scholar
• Wong LL, Chang CF, Koay ES, et al. Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancerprogression. Int J Oncol 2009;34:1291-301
   PubMed Web of Science ®Google Scholar
• Switzer CH, Cheng RY, Vitek TM, et al. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011;30:2504-13
   PubMed Web of Science ®Google Scholar
• Niemelä M, Kauko O, Sihto H, et al. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012;31:4266-78
   PubMed Web of Science ®Google Scholar
• Cristóbal I, Manso R, Rincón R, et al. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther 2014;13:938-47
   PubMed Web of Science ®Google Scholar
• Baldacchino S, Saliba C, Petroni V, et al. Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720. EPMA J 2014;5:3
   PubMedGoogle Scholar
• Janghorban M, Farrell AS, Allen-Petersen BL, et al. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci USA 2014;111:9157-62
   PubMed Web of Science ®Google Scholar
• Liu X, Peng B, Li Y, et al. p90/CIP2A mediates breast cancer cell proliferation and apoptosis. Mol Biol Rep 2014;41:7471-8
   PubMed Web of Science ®Google Scholar
• Cristóbal I, Rincón R, Manso R, et al. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. Biochim Biophys Acta 2014;1842:1823-9
   PubMed Web of Science ®Google Scholar
• Cristóbal I, Manso R, Rincón R, et al. Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer. Br J Cancer 2014;111:756-62
   PubMed Web of Science ®Google Scholar
• Cristóbal I, Rincón R, Manso R, et al. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. Clin Cancer Res 2015;21:347-56
   Google Scholar
• Bhardwaj A, Singh S, Srivastava SK, et al. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol Cancer Ther 2011;10:720-31
   PubMed Web of Science ®Google Scholar
• Bluemn EG, Spencer ES, Mecham B, et al. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Mol Cancer Res 2013;11:568-78
   PubMed Web of Science ®Google Scholar
• Pandey P, Seshacharyulu P, Das S, et al. Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. Br J Cancer 2013;108:2590-600
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Tabanor K, Chaguturu R, et al. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment. Cancer Biol Ther 2013;14:962-72
   PubMed Web of Science ®Google Scholar
• Cristóbal I, González-Alonso P, Daoud L, et al. Activation of the tumor suppressor PP2A emerges as a potential therapeutic strategy for treating prostate cancer. Mar Drugs 2015;13:3276-86
   PubMed Web of Science ®Google Scholar
• Hu X, Garcia C, Fazli L, et al. Inhibition of Pten deficient castration resistant prostate cancer by targeting of the SET-PP2A signaling axis. Sci Rep 2015;5:15182
   PubMed Web of Science ®Google Scholar
• González-Alonso P, Cristóbal I, Manso R, et al. PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer. Tumour Biol 2015;36:5753-5
   PubMed Web of Science ®Google Scholar
• Ma L, Wen ZS, Liu Z, et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One 2011;6:e20159
   Google Scholar
• Saddoughi SA, Gencer S, Peterson YK, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 2013;5:105-21
   PubMed Web of Science ®Google Scholar
• Lei N, Peng B, Zhang JY. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer. Oncol Rep 2014;32:1689-94
   PubMed Web of Science ®Google Scholar
• Liu H, Gu Y, Wang H, et al. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. Oncotarget 2015;6:14913-25
   PubMed Web of Science ®Google Scholar
• Hung MH, Wang CY, Chen YL, et al. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A. Oncotarget 2016;7:638-55
   PubMed Web of Science ®Google Scholar
• Chen KF, Liu CY, Lin YC, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010;29:6257-66
   PubMed Web of Science ®Google Scholar
• Yu HC, Hou DR, Liu CY, et al. Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. PLoS One; 2013;8:e55705
   PubMed Web of Science ®Google Scholar
• Yu HC, Hung MH, Chen YL, et al. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death Dis 2014;5:e1359
   PubMed Web of Science ®Google Scholar
• Routila J, Bilgen T, Saramäki O, et al. Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma. J Oral Pathol Med 2015; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Katz J, Jakymiw A, Ducksworth MK, et al. CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther 2010;10:694-9
   PubMed Web of Science ®Google Scholar
• Qu W, Li W, Wei L, et al. CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol 2012;29:113-18
   PubMed Web of Science ®Google Scholar
• Routila J, Mäkelä JA, Luukkaa H, et al. Potential role for inhibition of protein phosphatase 2A tumor suppressor in salivary gland malignancies. Genes Chromosomes Cancer 2016;55:69-81
   PubMed Web of Science ®Google Scholar
• Böckelman C, Hagström J, Mäkinen LK, et al. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer 2011;104:1890-5
   PubMed Web of Science ®Google Scholar
• McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011;223:567-73
   PubMed Web of Science ®Google Scholar
• Nagendra DC, Burke J, Maxwell GL, et al. PPP2R1A mutations are common in the serous type of endometrial cancer. Mol Carcinog 2012;51:826-31
   PubMed Web of Science ®Google Scholar
• Wu Y, Gu TT, Zheng PS. CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical cancer progression. Cancer Lett 2015;356:646-55
   PubMed Web of Science ®Google Scholar
• Huang LP, Savoly D, Sidi AA, et al. CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med 2012;1:76-81
   PubMed Web of Science ®Google Scholar
• Pang X, Fu X, Chen S, et al. Overexpression of CIP2A promotes bladder cancer progression by regulating EMT. Clin Transl Oncol 2015; [Epub ahead of print]
   Web of Science ®Google Scholar
• Farrell AS, Allen-Petersen B, Daniel CJ, et al. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Mol Cancer Res 2014;12:924-39
   PubMed Web of Science ®Google Scholar
• Chien W, Sun QY, Lee KL, et al. Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Mol Oncol 2015;9:889-905
   PubMed Web of Science ®Google Scholar
• Kalla C, Scheuermann MO, Kube I, et al. Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B. Eur J Cancer 2007;43:1328-35
   PubMed Web of Science ®Google Scholar
• Zonta F, Pagano MA, Trentin L, et al. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood 2015;125:3747-55
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhao X, Frissora F, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008;111:275-84
   PubMed Web of Science ®Google Scholar
• Christensen DJ, Chen Y, Oddo J, et al. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood 2011;118:4150-8
   PubMed Web of Science ®Google Scholar
• Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007;117:2408-21
   PubMed Web of Science ®Google Scholar
• Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005;8:355-68
   PubMed Web of Science ®Google Scholar
• Lucas CM, Harris RJ, Giannoudis A, et al. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 2011;117:6660-8
   PubMed Web of Science ®Google Scholar
• Wang J, Huang T, Sun J, et al. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus. Med Oncol 2014;31:112
   PubMed Web of Science ®Google Scholar
• Neviani P, Harb JG, Oaks JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013;123:4144-57
   PubMed Web of Science ®Google Scholar
• Cristóbal I, Blanco FJ, Garcia-Orti L, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010;115:615-25
   PubMed Web of Science ®Google Scholar
• Roberts KG, Smith AM, McDougall F, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT + cancers. Cancer Res 2010;70:5438-47
   PubMed Web of Science ®Google Scholar
• Cristóbal I, Garcia-Orti L, Cirauqui C, et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 2012;97:543-50
   PubMed Web of Science ®Google Scholar
• Yang Y, Huang Q, Lu Y, et al. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem 2012;113:1314-22
   PubMed Web of Science ®Google Scholar
• Cristóbal I, Cirauqui C, Castello-Cros R, et al. Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells. Haematologica 2013;98:e103-4
   Google Scholar
• Agarwal A, MacKenzie RJ, Pippa R, et al. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 2014;20:2092-103
   PubMed Web of Science ®Google Scholar
• Cristóbal I, Garcia-Orti L, Cirauqui C, et al. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011;25:606-14
   PubMed Web of Science ®Google Scholar
• Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 2013;14:e229-38
   PubMed Web of Science ®Google Scholar
• Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008;14:152-60
   PubMed Web of Science ®Google Scholar
• Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 1992;257:1261-4
   PubMed Web of Science ®Google Scholar
• Pippa R, Dominguez A, Christensen DJ, et al. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia 2014;28:1915-18
   PubMed Web of Science ®Google Scholar
• Xie F, Bao X, Yu J, et al. Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK. Oncotarget 2015;6:25660-76
   PubMed Web of Science ®Google Scholar
• Lee TK, Man K, Ho JW, et al. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 2005;11:8458-66
   PubMed Web of Science ®Google Scholar
• Lee TK, Man K, Ho JW, et al. Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. Carcinogenesis 2005;26:681-7
   PubMed Web of Science ®Google Scholar
• ten Klooster JP, Leeuwen I, Scheres N, et al. Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J 2007;26:336-45
   PubMed Web of Science ®Google Scholar
• Rietz A, Volkov Y, Davies A, et al. Okadaic acid induces matrix metalloproteinase-9 expression in fibroblasts: crosstalk between protein phosphatase inhibition and β-adrenoceptor signalling. Br J Pharmacol 2012;165:274-88
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Fazekas F. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med Wochenschr 2012;162:354-66
   Google Scholar
• Estella-Hermoso de Mendoza A, Castello-Cros R, Imbuluzqueta E, et al. Lipid nanosystems enhance the bioavailability and the therapeutic efficacy of FTY720 in acute myeloid leukemia. J Biomed Nanotechnol 2015;11:691-701
   PubMed Web of Science ®Google Scholar
• Omar HA, Chou CC, Berman-Booty LD, et al. Antitumor effects of OSU-2S, a non-immunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology 2011;53;1943-58
   PubMed Web of Science ®Google Scholar
• Cruz VT, Fonseca J. Central effects of fingolimod. Rev Neurol 2014;59:121-8
   PubMed Web of Science ®Google Scholar
• Voronkov M, Braithwaite SP, Stock JB. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer’s disease. Future Med Chem 2011;3:821-33
   PubMed Web of Science ®Google Scholar
• Vargas-Medrano J, Krishnamachari S, Villanueva E, et al. Novel FTY720-based compounds stimulate neurotrophin expression and phosphatase activity in dopaminergic cells. ACS Med Chem Lett 2014;5:782-6
   PubMed Web of Science ®Google Scholar